Enhancing Oral Delivery of Peptide Drugs Through Intestinal Permeation Boosters

Peptide drugs, while therapeutically potent, often face significant challenges in oral administration due to their susceptibility to enzymatic degradation in the gastrointestinal tract and their inherently low intestinal permeability. This poor absorption means most peptide therapies must be delivered via inconvenient and often painful injections, limiting patient compliance and accessibility. This study specifically addresses the critical knowledge gap of how to effectively enhance the transcellular permeation of peptide drugs across the intestinal barrier to enable viable oral formulations.

The study successfully demonstrated that specific transcellular permeation enhancers significantly improved the intestinal absorption of both peptide drugs. For Enalaprilat, certain enhancers led to a substantial 2.8-fold increase in systemic exposure compared to the control group, indicating a marked improvement in oral bioavailability. Similarly, Hexarelin absorption was enhanced, with the most effective enhancer resulting in a 1.9-fold increase in plasma concentrations, achieving statistically significant differences (p<0.01) over unenhanced delivery. > The most promising enhancer formulation achieved an impressive 180% increase in the oral bioavailability of Enalaprilat, transforming its absorption profile from negligible to therapeutically relevant levels. These findings suggest that carefully selected permeation enhancers can overcome the natural barriers to peptide drug absorption, offering a viable pathway for oral delivery.